Skip to content

Gastrointestinal issues caused by metformin use: what are the treatment alternatives?

Occurrence of gastrointestinal adverse events and the use of metformin hydrochloride: are there other management options?

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-3wn6k3p
Enrollment
Unknown
Registered
2025-01-17
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea

Interventions

This is a multicenter, triple-blind, parallel, randomized clinical trial that will evaluate folic acid supplementation and the occurrence of diarrhea in patients with type II diabetes mellitus who wil

Sponsors

Universidade Federal de São João del-Rei
Lead Sponsor
Universidade Federal de São João del-Rei
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Male and female patients will be recruited. Age over 18 years. Patients using 500 mg immediate-release metformin hydrochloride for the first time

Exclusion criteria

Exclusion criteria: Pregnant women. Patients with a history of or declared allergies to folic acid. Those considered incapable of completing the adverse event perception form accurately: for the latter exclusion criterion, the patient's level of education and the presence or absence of a caregiver will be considered

Design outcomes

Primary

MeasureTime frame
It is expected to observe a reduction in diarrhea related to the use of immediate-release metformin hydrochloride 500 mg in the group receiving folic acid supplementation (intervention), assessed through the adverse event perception form over the 30 days following the initiation of the medicine

Secondary

MeasureTime frame
It is expected to observe a reduction in abdominal discomfort related to the use of immediate-release metformin hydrochloride 500 mg in the group receiving folic acid supplementation (intervention), assessed through the adverse event perception form over the 30 days following the initiation of the medicine;It is expected to observe a lower impact of gastrointestinal adverse events on daily activities, energy levels, mood, family life, and social interactions related to the use of immediate-release metformin hydrochloride 500 mg in the group receiving folic acid supplementation (intervention), assessed through the adverse event perception form over the 30 days following the initiation of the medicine

Countries

Brazil

Contacts

Public ContactAngelo Meri Junior

Universidade Federal de São João del-Rei

angeloemj0001@aluno.ufsj.edu.br+55 (37) 36904450

Outcome results

None listed

Source: REBEC (via WHO ICTRP)